Hims & Hers is returning to the Super Bowl — one year after its debut spot kicked up a storm of controversy. The telehealth ...

In less than two weeks, more than 120 million people are expected to tune into the biggest advertising moment of the year: ...

Narrated by Common, Hims & Hers' 2026 Super Bowl ad positions affordability as part of the solution to the income disparities ...

The telehealth company is back in the fourth quarter of the Big Game, a year after its weight-loss ad drew regulatory and ...

"We fully expect this will ruffle some feathers," Hims & Hers chief design officer, Dan Kenger, told Business Insider.

Advanced cancer detection, hormone therapies and microdoses of GLP-1 sound like medical treatments for the rich and chic. One ...

Hims & Hers is a Strong Buy, as shares appear historically cheap due to temporary margin compression and regulatory concerns. Click here to read more.

Hims & Hers is quietly building a healthcare platform, aiming to control the primary interface for diagnostics, prevention, and personalized treatments. Learn more.

Last year, Hims & Hers put out a Super Bowl ad—the first for the telehealth giant—that sparked both support and outrage for the way it claimed that Big Pharma prices GLP-1s “ for profits, not patients ...

Investors interested in stocks from the Medical Info Systems sector have probably already heard of Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks presents investors ...